27552 Federal Register / Vol. 74, No. 110 / Wednesday, June 10, 2009 / Notices 

FOR FURTHER INFORMATION CONTACT: 

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 513– 

533–6800 (this is not a toll-free 

number). Information requests can also 

be submitted by e-mail to 

OCAS@CDC.GOV. 

Christine M. Branche, 

Acting Director, National Institute for 

Occupational Safety and Health. 

[FR Doc. E9–13662 Filed 6–9–09; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the National Coordinator for 

Health Information Technology; HIT 

Standards Committee Meeting 

ACTION: Announcement of meeting. 

SUMMARY: This notice announces the 

second meeting of the HIT Standards 

Committee in accordance with the 

Federal Advisory Committee Act (Pub. 

L. No. 92–463, 5 U.S.C., App.). 

DATES: June 23, 2009, from 9 a.m. to 12 

p.m. [Eastern] 

ADDRESSES: The Omni Shoreham Hotel, 

2500 Calvert Street, NW., Washington, 

DC 20008, Diplomat Ballroom. 

FOR FURTHER INFORMATION CONTACT: 

http://healthit.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

The meeting will include 

presentations from the HIT Standards 

Committee Workgroups. The meeting is 

a Web-based meeting with 

teleconference dial-in. If you have 

special needs for the meeting, please 

contact (202) 690–7151. 

Judith Sparrow, 

Office of Programs and Coordination, Office 

of the National Coordinator for Health 

Information Technology. 

[FR Doc. E9–13630 Filed 6–9–09; 8:45 am] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; Comment 

Request; Investigator Registration and 

Financial Disclosure for Investigational 

Trials in Cancer Treatment (NCI) 

SUMMARY: In compliance with the 

requirement of Section 3506(c)(2)(A) of 

the Paperwork Reduction Act of 1995, 

for opportunity for public comment on 

proposed data collection projects, the 

National Cancer Institute, the National 

Cancer Institute (NIH) will publish 

periodic summaries to the Office of 

Management and Budget (OMB) for 

review and approval. 

Proposed Collection: Title: 

Investigator Registration and Financial 

Disclosure for Investigational Trials in 

Cancer Treatment (NCI). Type of 

Information Collection Request: Existing 

Collection in use without an OMB 

Control Number. Need and Use of 

Information Collection: Food and Drug 

Administration (FDA) regulations 

require sponsors to obtain information 

from the investigator before permitting 

the investigator to begin participation in 

investigational studies. The National 

Cancer Institute (NCI), as a sponsor of 

investigational drug trials, has the 

responsibility to assure the FDA that 

investigators in its clinical trials 

program are qualified by training and 

experience as appropriate experts to 

investigate the drug. In order to fulfill 

these requirements, a standard 

Statement of Investigator (FDA Form 

1572 modified), Supplemental 

Investigator Data Form, Financial 

Disclosure Form and Curriculum vitae 

(CV) are required. The data obtained 

from these forms allows the NCI to 

evaluate the qualifications of the 

investigator, identify appropriate 

personnel to receive shipment of 

investigational agent, ensure supplies 

are not diverted for inappropriate 

protocol or patient use and identify 

financial conflicts of interest. 

Comparisons are done with the 

intention of ensuring protocol, patient 

safety and drug compliance for patient 

and drug compliance for patient safety 

and protections. 

Frequency of Response: Annually. 

Affected Public: Public sector, 

businesses other for-profit. Federal 

agencies or employees, non-profit 

institutions and a very small number of 

private practice physicians. 

Type of Respondents: Health care 

investigators. The annual reporting 

burden is limited to those physicians 

who choose to participate in NCI 

sponsored investigational trials to 

identify new medicinal agents to treat 

and relieve those patients suffering from 

cancer. It is estimated that the total 

annual burden will be 8,564 hours, and 

include 17,128 investigators, for this 

project (see Table 1). 

TABLE 1—ESTIMATES OF ANNUAL BURDEN

Type of respondents Form Number of respondents 

Frequency of 

response Average time per response Total hour burden 

Investigators and Designee ... Statement of Investigator ..... 17,128 1 0.25 (15 minutes) ................. 4,282 

Supplemental Investigator .... 17,128 1 0.167 (10 minutes) ............... 2,855 

Financial Disclosure ............. 17,128 1 0.083 (5 minutes) ................. 1,427 

Totals .............................. ............................................... 17,128 ........................ ............................................... 8,564 

There is no capital, operating or 

maintenance costs to report. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information; including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Charles L. Hall, Jr., 

Chief, Pharmaceutical Management 

Branch, Cancer Therapy Evaluation 

Program, Division of the Cancer 

Treatment and Diagnosis, and Centers, 

National Cancer Institute, Executive 

Plaza North, Room 7148, 9000 Rockville 

Pike, Bethesda, MD 20892 or call nontoll-free number 301–496–5725 or EVerDate Nov<24>2008 15:18 Jun 09, 2009 Jkt 217001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\10JNN1.SGM 10JNN1

erowe on PROD1PC63 with NOTICES
Federal Register / Vol. 74, No. 110 / Wednesday, June 10, 2009 / Notices 27553 

mail your request, including your 

address to: Hallch@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60 days following the 

date of this publication. 

Dated: June 3, 2009. 

Vivian Horovitch-Kelley, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. E9–13627 Filed 6–9–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Respirable 

Dust Control Related to Mining, 

Program Announcement Number (PA) 

07–318, Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 9 a.m.–5 p.m., July 14, 

2009 (Closed). 

Place: Marriott Waterfront, 700 Aliceanna 

Street, Baltimore, Maryland 21202; 

Telephone: (410) 385–3000. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters to be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Respirable Dust Control Related 

to Mining, PA 07–318.’’ 

Contact Person for More Information: 

George Bockosh, Scientific Review 

Administrator, Office Of Extramural 

Programs, National Institute for Occupational 

Safety and Health, CDC, 1600 Clifton Road, 

NE., Mailstop P05, Atlanta Georgia 30333; 

Telephone: (412) 352–5181; 

GBockosh@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: June 3, 2009. 

Lorenzo Falgiano, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E9–13557 Filed 6–9–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Council for the Elimination of 

Tuberculosis Meeting (ACET) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Times and Dates: 

8:30 a.m.–4:30 p.m., July 14, 2009. 

8:30 a.m.–2:30 p.m., July 15, 2009. 

Place: Corporate Square, Building 8, 1st 

Floor Conference Room, Atlanta, Georgia 

30333, Telephone (404) 639–8317. 

Status: Open to the public, limited only by 

the space available. The meeting room 

accommodates approximately 100 people. 

Purpose: This council advises and makes 

recommendations to the Secretary of Health 

and Human Services, the Assistant Secretary 

for Health, and the Director, CDC, regarding 

the elimination of tuberculosis. Specifically, 

the Council makes recommendations 

regarding policies, strategies, objectives, and 

priorities; addresses the development and 

application of new technologies; and reviews 

the extent to which progress has been made 

toward eliminating tuberculosis. 

Matters To Be Discussed: Agenda items 

include issues pertaining to tuberculosis in 

special populations; Federal agencies and 

their role in global tuberculosis control and 

research; and research updates and other 

related tuberculosis issues. Agenda items are 

subject to change as priorities dictate. 

Contact Person for More Information: 

Margie Scott-Cseh, Coordinating Center for 

Infectious Diseases, Strategic Business Unit, 

1600 Clifton Road, NE., Mailstop E–07, 

Atlanta, Georgia 30333, Telephone (404) 

639–8317. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register Notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: June 3, 2009. 

Lorenzo Falgiano, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E9–13558 Filed 6–9–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Member 

Conflict Review, Program 

Announcement Number (PA) 07–318, 

Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 1 p.m.–3 p.m., July 22, 

2009 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Member Conflict Review, PA 

07–318.’’ 

Contact Person for More Information: Chris 

Langub, Scientific Review Administrator, 

Office Of Extramural Programs, National 

Institute for Occupational Safety and Health, 

CDC, 1600 Clifton Road, NE., Mailstop E74, 

Atlanta, Georgia 30333; Telephone: (404) 

498–2543. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: June 3, 2009. 

Lorenzo Falgiano, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E9–13559 Filed 6–9–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Injury Prevention 

and Control Initial Review Group, 

(NCIPC IRG) 

Times and Dates: 12:30 p.m.–7 p.m. 

(Closed) 

Correction: This notice was published 

in the Federal Register on May 19, 

2009, Volume 74, Number 95, Page 

23423. The timeframe for the closed 


erowe on PROD1PC63 with NOTICES